GlaxoSmithKline has booked a 2 percent dip in revenues for the first quarter to £7.2 billion, after results were hit by a “significant currency impact” and lower sales of prescription drugs.
GlaxoSmithKline’s new chief executive Emma Walmsley has unveiled her strategy for the company, saying its pharma division must focus more on its key assets and deliver ‘full value’ from launches.